Biophytis (NASDAQ:BPTS) stock is rocketing higher on Tuesday after announcing a production partnership with SEQENS.
According to a press release, Biophytis will work with SEQENS for the production of the active ingredient in Sarconeos. This will see SEQENS handle the production of the compound at its Villeneuve La Garenne plant in France.
Sarconeos is Biophytis’ lead candidate in development to treat several issues. That includes “severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.”
Stanislas Veillet, chairman and CEO of Biophytis, said the following about the production agreement news:
“SEQENS’ proven know-how and compliance with manufacturing standards will be decisive in meeting our needs over the next few years, particularly in the context of early access programs and with a view to market access applications for Sarconeos (BIO101) in the treatment of severe forms of Covid-19.”
BPTS Stock Movement Today
With this latest announcement, shares of BPTS stock are experiencing heavy trading on Tuesday. That has more than 3.6 million shares changing hands as of this writing. To put that number in perspective, the company’s daily average trading volume is only about 10,000 shares.
Investors will also keep in mind that BPTS is a penny stock. While today’s movement does come from positive news, it may be a bit exaggerated as investors buy up more shares due to its low entry point.
BPTS stock is up 66% as of Tuesday morning.
Investors seeking out more of the most recent stock market news will want to keep reading!
InvestorPlace is home to all of the hottest stock market news for Tuesday! That includes the biggest pre-market stock movers this morning, the latest news concerning shares of solar stocks and more. You can catch up on all of this news at the links below!
More Tuesday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Why Are Solar Stocks Up Today?
- Dear NVDA Stock Fans, Mark Your Calendars for July 24
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
